MET Human shRNA Plasmid Kit (Locus ID 4233)
CAT#: TL320418
MET - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Cited in 1 publication. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
CNY 1,999.00
CNY 2,700.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | MET Human shRNA Plasmid Kit (Locus ID 4233) |
Locus ID | 4233 |
UniProt ID | P08581 |
Synonyms | AUTS9; c-Met; DFNB97; HGFR; RCCP2 |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | MET - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 4233). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_000245, NM_001127500, NM_001324401, NM_001324402, NM_000245.1, NM_000245.2, NM_000245.3, NM_001127500.1, NM_001127500.2, BC016592, BC027979, BC127890, BC130420, NM_001127500.3, NM_000245.4 |
Summary | This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis
,Yao, JF;Li, XJ;Yan, LK;He, S;Zheng, JB;Wang, XR;Zhou, PH;Zhang, L;Wei, GB;Sun, XJ;,
J. Biochem. Mol. Toxicol.
,PubMed ID 30897285
[MET]
|
Documents
Product Manuals |
FAQs |
SDS |